Literature DB >> 10913511

Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.

A Winokur1, M J Sateia, J B Hayes, W Bayles-Dazet, M M MacDonald, K A Gary.   

Abstract

BACKGROUND: Mirtazapine, a clinically effective antidepressant, acts by antagonizing central alpha2-adrenergic and 5-HT2/5-HT3 receptors. No data are available regarding mirtazapine's effects on sleep architecture in patients with major depressive disorder.
METHODS: Six patients meeting criteria for major depressive disorder and scoring > or =4 on the three Hamilton Depression Rating Scale sleep items were studied. Polysomnographic evaluations were performed at baseline and after 1 (15 mg at bedtime) and 2 weeks (30 mg at bedtime) of open-label mirtazapine treatment.
RESULTS: Mirtazapine significantly decreased sleep latency and significantly increased total sleep time and sleep efficiency from baseline levels during week 1, with similar results observed after week 2. Mirtazapine did not significantly alter rapid eye movement sleep parameters. Clinically, Hamilton Depression Rating Scale and sleep disturbance ratings improved after treatment.
CONCLUSIONS: Mirtazapine significantly improves sleep continuity in major depressive disorder patients with poor sleep quality at weeks 1 and 2 of treatment, while preserving sleep architecture.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913511     DOI: 10.1016/s0006-3223(00)00882-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  18 in total

1.  Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.

Authors:  Neely Ivgy-May; Goeran Hajak; Gonnie van Osta; Sabine Braat; Qing Chang; Thomas Roth
Journal:  J Clin Sleep Med       Date:  2020-09-15       Impact factor: 4.062

2.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

Review 3.  Treatment options for sleep disturbances during alcohol recovery.

Authors:  J Todd Arnedt; Deirdre A Conroy; Kirk J Brower
Journal:  J Addict Dis       Date:  2007

4.  Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Authors:  Jared Minkel; Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2013-09-01

5.  Comparison of different methods for the evaluation of treatment effects from the sleep EEG of patients with major depression.

Authors:  V Carolina Figueroa Helland; Svetlana Postnova; Udo Schwarz; Jürgen Kurths; Bernd Kundermann; Ulrich Hemmeter; Hans A Braun
Journal:  J Biol Phys       Date:  2008-07-31       Impact factor: 1.365

Review 6.  Use of sleep-promoting medications in nursing home residents : risks versus benefits.

Authors:  David K Conn; Robert Madan
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Doxepin in children and adolescents with symptoms of insomnia: a single-center experience.

Authors:  Yash D Shah; Virginia Stringel; Ivan Pavkovic; Sanjeev V Kothare
Journal:  J Clin Sleep Med       Date:  2020-02-07       Impact factor: 4.062

8.  Predictors of start of different antidepressants in patient charts among patients with depression.

Authors:  Hyungjin Myra Kim; Kara Zivin; Hae Mi Choe; Clare M Stano; Dara Ganoczy; Heather Walters; Marcia Valenstein
Journal:  J Manag Care Spec Pharm       Date:  2015-05

Review 9.  Psychiatric disorders and sleep.

Authors:  Andrew D Krystal
Journal:  Neurol Clin       Date:  2012-11       Impact factor: 3.806

Review 10.  Insomnia in patients with depression: some pathophysiological and treatment considerations.

Authors:  Ripu D Jindal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.